Internal Medicine, Endocrinology, Diabetes, & Metabolism · Jacksonville, FL
NPI
1902869837
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
915 W Monroe St Ste 200
Jacksonville, FL, 32204
Phone (904) 384-2240
Groups this clinician bills Medicare through
Medicare paid, 2024
$209K
4,079 services
Medicare patients, 2024
1,045
Average age 74
Drug cost, 2024
$3.7M
9,307 prescriptions
Company payments, 2025
$2,799
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anil P Shrestha was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 1,245 times for 730 patients. In total Anil P Shrestha billed 4,079 services in 17 codes, and Medicare paid $209K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-02-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,245 | 730 | $11.63 | $14K |
| 99214 Office E&M - Established | Office | 1,022 | 583 | $87.60 | $90K |
| 99213 Office E&M - Established | Office | 783 | 561 | $60.39 | $47K |
| 95251 Test - Miscellaneous | Office | 415 | 188 | $25.33 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 307 | 87 | $61.09 | $19K |
| 99204 Office E&M - New | Office | 102 | 102 | $117.81 | $12K |
| 76536 Ultrasound - Nonspecific | Office | 88 | 87 | $78.32 | $6,892 |
| 99223 Hospital E&M - Initial | Facility | 54 | 49 | $124.13 | $6,703 |
| G0108 Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 21 | 11 | $38.19 | $802 |
| 99212 Office E&M - Established | Office | 18 | 18 | $34.41 | $619 |
By year: 2022 $218K for 3,156 services; 2023 $203K for 3,015 services; 2024 $209K for 4,079 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 12 | 12 | $3.00 | $36 |
Medicare prescription drug claims, 2024
In 2024, the drug Anil P Shrestha prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,089 prescriptions and refills. In total Anil P Shrestha wrote 9,307 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,089 | 2,812 | 286 | $13K |
| Ozempic Semaglutide | 748 | 984 | 146 | $921K |
| Metformin Hcl Generic | 476 | 1,233 | 147 | $3,632 |
| Jardiance Empagliflozin | 374 | 667 | 79 | $372K |
| Synthroid Levothyroxine Sodium | 359 | 891 | 86 | $30K |
| Methimazole Generic | 286 | 565 | 68 | $2,191 |
| Rosuvastatin Calcium Generic | 266 | 620 | 80 | $2,660 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 260 | 689 | 86 | $54K |
| Glipizide Generic | 258 | 603 | 70 | $1,966 |
| Tresiba Flextouch U-100 Insulin Degludec | 237 | 576 | 84 | $175K |
| Novolog Flexpen Insulin Aspart | 236 | 504 | 94 | $62K |
| Humalog Kwikpen U-100 Insulin Lispro | 212 | 449 | 68 | $74K |
| Farxiga Dapagliflozin Propanediol | 190 | 281 | 39 | $150K |
| Trulicity Dulaglutide | 168 | 238 | 33 | $220K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 167 | 371 | 58 | $15K |
Brand drugs: 5,138 claims; generic drugs: 3,466 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anil P Shrestha $2,799 ($2,799 in general payments such as food, travel and fees) from 30 companies. The largest payer was Insulet Corporation with $432.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 29 | $432 |
| Xeris Pharmaceuticals, Inc. | 12 | $240 |
| Dexcom, Inc. DXCM | 9 | $212 |
| Novo Nordisk Inc NVO | 13 | $193 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 8 | $149 |
| Sanofi-Aventis U.S. LLC SNY | 6 | $145 |
| Lilly USA, LLC LLY | 7 | $139 |
| Medtronic, Inc. MDT | 8 | $138 |
| Amgen Inc. AMGN | 8 | $135 |
| CeQur Corporation | 1 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.